Ovid Application Error
First report of overall survival for ipilimumab plus nivolumab from the phase III Checkmate 067 study in advanced melanoma. Turajlic, S; Gore, M; Larkin, J [Editorial] Annals of Oncology. 29(3):542-543, March 2018.
(Format: HTML)